Ascendis Pharma Past Earnings Performance

Past criteria checks 0/6

Ascendis Pharma's earnings have been declining at an average annual rate of -15%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 73.3% per year.

Key information

-15.0%

Earnings growth rate

-11.6%

EPS growth rate

Biotechs Industry Growth12.9%
Revenue growth rate73.3%
Return on equityn/a
Net Margin-130.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ascendis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BMV:ASND N Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24327-426275319
30 Jun 24318-490269356
31 Mar 24329-502265378
31 Dec 23267-481264413
30 Sep 23152-602257431
30 Jun 23119-609254417
31 Mar 2378-569240403
31 Dec 2251-583221380
30 Sep 2233-482213337
30 Jun 2219-393192298
31 Mar 2214-446170291
31 Dec 218-384160296
30 Sep 213-416132491
30 Jun 215-458111432
31 Mar 215-41896349
31 Dec 207-41977261
30 Sep 209-3607350
30 Jun 208-26466192
31 Mar 2010-22856140
31 Dec 1913-21848192
30 Sep 1921-17040179
30 Jun 1919-1783770
31 Mar 1916-14231161
31 Dec 1811-13025140
30 Sep 180-13221130
30 Jun 181-13217128
31 Mar 181-14015110
31 Dec 172-12413100
30 Sep 172-1061392
30 Jun 173-911279
31 Mar 174-731270
31 Dec 165-691266
30 Sep 166-641259
30 Jun 166-531050
31 Mar 167-551049
31 Dec 158-33941
30 Sep 159-26836
30 Jun 1510-21831
31 Mar 1512-8823
31 Dec 1414-10620
30 Sep 1417-2415
30 Jun 14200315
31 Mar 14203313
31 Dec 13204213

Quality Earnings: ASND N is currently unprofitable.

Growing Profit Margin: ASND N is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ASND N is unprofitable, and losses have increased over the past 5 years at a rate of 15% per year.

Accelerating Growth: Unable to compare ASND N's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ASND N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.6%).


Return on Equity

High ROE: ASND N's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies